Company intelligence / Profile preview

InSphero

Schlieren, Zurich, Switzerlandinsphero.com ↗

Ownership: Private
Development stage: Commercial

Overview

InSphero does not develop its own clinical-stage therapeutics. Its 3D microtissue platforms are validated by major pharmaceutical companies worldwide to improve preclinical decision-making in drug discovery. Their technologies have been used in collaborative industry initiatives such as EU-ToxRisk and HeCaToS and are cited in peer-reviewed publications for advancing non-animal drug testing methods.

Therapeutic areas: GastroenterologyCardiovascularMetabolic DisordersOncology
Modalities: 3D cell-based models (microtissues and organoids)
Industry: Non-Drug Biotech

Partnerships

Collaborations with major pharmaceutical companies globallyIndustry consortia such as EU-ToxRisk and HeCaToS projectsStrategic investment from ZEISS Ventures to drive imaging/analysis capabilities

Beyond the preview

Go deeper on InSphero.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InSphero.

Explore the full profile